SubsidieMeestersbiomimetic engineered chordae tendineae for valve repair and regeneration
This project aims to develop and validate BioChord, a bioengineered regenerative chordae tendineae for mitral valve repair, enhancing durability and promoting tissue restoration.
Projectdetails
Introduction
The human heart is among those organs suffering from a limited capacity to self-regenerate. Heart diseases continue to be a leading cause of mortality with suboptimal therapeutic options. Thus, deploying new therapeutic strategies for tissue repair is a primary objective in modern cardiac medicine.
Valvular Heart Diseases
Valvular heart diseases, such as those related to the Mitral Valve (MV), are the leading causes of cardiovascular morbidity and mortality worldwide, affecting 5.1% of the 65+ years old population. In particular, MV regurgitation, one of the most common valvopathies, affects over 24 million people worldwide.
Nature of MV Regurgitation
Since the fundamental nature of MV regurgitation is mechanical, caused by physical, irreversible damage to the restraining force structures of the valvular apparatus, the only effective treatment is limited to the surgical approaches that include MV repair or replacement.
Treatment Options
However, when the regurgitation is due to Chordae Tendinae (CT) elongation or rupture, several studies have demonstrated the substantial advantages of MV repair, using a substitute for the damaged CT vs. MV replacement. Currently, the expanded polytetrafluoroethylene (ePTFE) has become the standard approach in CT repair/replacement.
Complications
However, several complications have been observed, including:
- Rupture
- Calcification
- Detachment
- Fibrosis
- Slippage
Hence, there continues to be an urgent need to develop better MV repair techniques that are simple, effective, and durable.
Proposal Overview
In this proposal, we intend to further advance and validate BioChord, the first ever polymeric bioengineered regenerative CT, designed to:
- Repair the MV by replacing the diseased CT.
- Provide mechanical support to the valvular apparatus.
- Be restored by the patient tissue, progressively becoming a functional tendon-like structure.
As a native CT, it will connect the valve leaflet to the papillary muscle and sustain the valvular apparatus with blood and nutrients.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-10-2023 |
| Einddatum | 31-3-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- FONDAZIONE RI.MEDpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTsG-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease. | ERC Starting... | € 1.497.351 | 2022 | Details |
Restoring anisotropy in living tissues 'in situ'This project aims to enhance cardiac tissue regeneration by restoring structural anisotropy using ultrasound, improving therapy outcomes through a multidisciplinary and technology-driven approach. | ERC Advanced... | € 3.056.887 | 2022 | Details |
Universal Cardiac Mesoangioblasts for treating DMD Dilated CardiomyopathyThe project aims to develop immune-privileged cardiac mesoangioblasts that can be converted to cardioblasts for targeted treatment of dilated cardiomyopathy, enhancing heart repair. | ERC Proof of... | € 150.000 | 2025 | Details |
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profilesProtego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications. | ERC Starting... | € 1.498.295 | 2024 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs
G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.
Restoring anisotropy in living tissues 'in situ'
This project aims to enhance cardiac tissue regeneration by restoring structural anisotropy using ultrasound, improving therapy outcomes through a multidisciplinary and technology-driven approach.
Universal Cardiac Mesoangioblasts for treating DMD Dilated Cardiomyopathy
The project aims to develop immune-privileged cardiac mesoangioblasts that can be converted to cardioblasts for targeted treatment of dilated cardiomyopathy, enhancing heart repair.
Prognostic assessment of valvular aortic disease treatment coupling Immunological and biomechanical profiles
Protego aims to develop a predictive methodology combining immunological and biomechanical profiles to optimize treatment timing and outcomes for patients with aortic valve diseases, reducing complications.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetimeGrOwnValve aims to revolutionize heart valve technology by creating lifelong autologous valves from patients' own tissue using 3D printing, reducing rejection and the need for multiple surgeries. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Engineering a living human Mini-heart and a swimming Bio-robotThe project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease. | EIC Pathfinder | € 4.475.946 | 2022 | Details |
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgansTHOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants. | EIC Pathfinder | € 3.994.150 | 2023 | Details |
Advancing Transcatheter Mitral Valve RepairThe Mitral butterfly implant is a self-expanding device designed to stabilize the heart's posterior leaflet, enhancing coaptation and minimizing surgical complexity during delivery. | EIC Accelerator | € 2.499.999 | 2023 | Details |
A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetime
GrOwnValve aims to revolutionize heart valve technology by creating lifelong autologous valves from patients' own tissue using 3D printing, reducing rejection and the need for multiple surgeries.
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
Engineering a living human Mini-heart and a swimming Bio-robot
The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.
building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans
THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.
Advancing Transcatheter Mitral Valve Repair
The Mitral butterfly implant is a self-expanding device designed to stabilize the heart's posterior leaflet, enhancing coaptation and minimizing surgical complexity during delivery.